Research Article | Open Access
Le Chen, Chenghong Zhang, Ying Han, Xianyi Meng, Ying Zhang, Haiying Chu, Haiying Ma, "Gingko biloba Extract (EGb) Inhibits Oxidative Stress in Neuro 2A Cells Overexpressing APPsw", BioMed Research International, vol. 2019, Article ID 7034983, 9 pages, 2019. https://doi.org/10.1155/2019/7034983
Gingko biloba Extract (EGb) Inhibits Oxidative Stress in Neuro 2A Cells Overexpressing APPsw
Alzheimer’s disease (AD) is a common neurodegenerative disease. Abundant evidence demonstrates that oxidative stress may be not only an early event in this disease, but also a key factor in the pathogenesis of AD. Ginkgo biloba extract (EGb) has a strong ability to scavenge oxygen free radicals and supply hydrogen. The present study aims to investigate the effects of EGb on Neuro 2A cells transfected with Swedish mutant APP (APPsw). Stably transfected Neuro 2A cell lines expressing human wild-type APP (APP695), APPsw, or empty vector(neo) pEGFP-N2 were treated with 100 μg/ml EGb for 0, 2, 4, 6, 8, and 10 h. Oxidative stress was assessed by measuring free radicals and the activities of antioxidant enzymes. Our studies showed that EGb treatment reduced the production of reactive oxygen species (ROS) and the levels of malondialdehyde (MDA) significantly while total superoxide dismutase (T-SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities were enhanced in Neuro 2A cells overexpressing APPsw. Meanwhile, Aβ levels in these cells were also reduced compared to the levels in untreated cells and control cells (empty vector(neo) pEGFP-N2). These findings suggest that EGb can reduce oxidative stress by decreasing free radical and enhancing antioxidant status, further leading to reduced Aβ aggregation; EGb might be a potential therapeutic agent for Alzheimer’s disease (AD).
Alzheimer’s disease (AD) is a neurodegenerative disease with progressive cognitive dysfunction and memory impairment and is the main cause of dementia in elderly people over 60 years old. AD is characterized by neuronal loss, extracellular deposits of β-amyloid (Aβ) in senile plaques and intraneuronal neurofibrillary tangles [1, 2]. According to the “Aβ cascade hypothesis” mechanism, Aβ is a key protein in AD pathology that is derived from the processing of transmembrane amyloid precursor protein (APP) by different secretases.
A large body of evidence has shown that free radicals may be involved in the etiopathogenesis of AD, and oxidative stress in neurons precedes and accompanies the accumulation of Aβ in AD [3–8]. Oxidative stress increases β- and γ-secretase activity and promotes the accumulation and deposition of Aβ. On the other hand, Aβ can promote the occurrence of oxidative stress, eventually forming a vicious circle and causing irreversible oxidative damage [9–11]. In addition, it is believed that oxidative damage to critical molecules occurs early in the pathogenesis of AD and precedes pronounced neuropathological alterations . Because oxidative damage begins early in the progression of the disease, it represents a potential therapeutic target for slowing the onset and progression of AD .
Ginkgo biloba extract (EGb) is derived from the leaves of Ginkgo biloba and its main active constituents are flavonoid glycosides, bilobalide, and ginkgolides. EGb can remove excessive oxygen free radicals, inhibit lipid peroxidation of cell membranes, inhibit inflammation and allergic reactions, and modulate immune responses, and it also has a strong hydrogen supply capacity . Many studies have shown that the effects of EGb involve its antioxidant properties [15, 16].
Therefore, in the current study, Neuro 2A (N2a) cells transfected with human APP695 and its Swedish mutant APPsw were used as an in vitro model of AD. We investigated the effect of EGb on this AD model. We examined cellular eactive oxygen species (ROS) production and assessed changes in intracellular malondialdehyde (MDA), total superoxide dismutase (T-SOD), catalase (CAT), and glutathione peroxidase (GSH-Px). The findings indicated that EGb showed significant antioxidant effects in N2a-APPsw cells, which may delay the onset and progression of AD.
2. Materials and Methods
2.1. Cell Culture, Transfection, and Treatment
N2a cells were cultured in MEM-GlutaMAX media (HyClone, USA) supplemented with 10% FBS (BI), 100 U/ml penicillin, and 100 μg/ml streptomycin in a 5% CO2 humidified atmosphere at 37°C. Stably transfected N2a cell lines expressing human APP695 and APPsw or the empty vector(neo) pEGFP-N2 were established by using the Effectene Transfection Reagent (QIAGEN, Germany) and selected by G418 resistance.
Cells were treated with 0, 50, 100, 200, or 400 μg/ml EGb (final concentration) for 8 h for the CCK-8 assay; treated with 100 μg/ml EGb for 0, 2, 4, 6, 8, or 10 h for the ROS assay; and treated with 100 μg/ml EGb for 8 h for the MDA, T-SOD, CAT, and GSH-Px assays. Cells in the control group were treated with DMEM medium alone as the vehicle.
2.2. CCK-8 Assay
Cell viability was measured in 96-well plates by CCK-8 assay. Briefly, after cells were treated with vehicle or EGb for the indicated time, 100 μl CCK-8 was added to the medium and then incubation continued at 37°C for 1 h. The absorbance at 450 nm was measured using a microplate reader (Thermo Scientific). The cell viability was expressed as the ratio of the signal obtained from the treated group to the control group.
2.3. Western Blot Assay
The cells were lysed on ice with precooled lysis buffer. After centrifugation at 12,000 rpm for 15 min at 4°C, the total protein concentration of each experimental group was quantified using a BCA kit (Beyotime Biotechnology, China). Equivalent protein lysates (30 μg) were separated by 10% SDS-PAGE gels and blotted onto PVDF membranes (Millipore, USA). Proteins were detected by using antibodies anti-APP (1:1000, Sigma, USA) and anti-β-actin (1:1000, Santa Cruze, USA) overnight at 4°C. After incubation with the secondary antibody, signals were visualized using an enhanced chemiluminescence detection kit (Advansta, USA) and quantified using Quantitative One Image Analysis (BioRad, USA).
2.4. Immunofluorescence Staining
Cells were seeded in 12-well slides (Solarbio, China) and treated as described above. The slides were washed with ice-cold PBS, fixed with 4% PFA at room temperature for 15 min, washed 3 times with PBS, and incubated with a 5% BSA blocking solution at room temperature for 2 h. The slides were incubated with rabbit anti-Aβ (1:200, Cell Signaling Technology) antibody overnight at 4°C. After washing with PBS, and the sample were incubated with Alexa Fluor-488 conjugated goat anti-rabbit antibody (1:300, Vector laboratories, USA) at room temperature for 2 h. Cells were examined using a fluorescence microscope (Olympus, Japan), and the mean optical density was quantified using Image-pro plus 5.1 software.
2.5. Oxidative Stress Assays: MDA, T-SOD, CAT, and GSH-Px Content Measurement
Cells cultured for 24 h in 6-well plates (4 × 104 cells/well) were treated with vehicle or 100 μg/ml EGb for 8 h. Cells were digested with trypsin and centrifuged at 1000 rpm for 5 min. Thereafter, the cells were suspended in 500 μl PBS, and lysed by sonication in the presence of a protease inhibitor, followed by centrifugation at 4000 rpm for 15 min. The supernatant was collected for analysis, according to the assay kits (JianCheng Biology, China) manufacturer’s instructions. MDA absorbance was recorded at 532 nm, and the results were calculated and expressed as nmol/mg protein. T-SOD, CAT, and GSH-Px in the cell homogenates were determined by colorimetry analysis at 550, 405, and 412 nm, respectively. The activities of these enzymes are expressed as U/mg protein.
2.6. ROS Production
Intracellular ROS levels were measured using the redox-sensitive fluorescent dye, DCFH-DA from ROS assay kits (Beyotime, China). Conversion of nonfluorescent DCFH-DA to fluorescent dichlorofluorescein (DCF) in the presence of ROS was measured on a microplate reader. In brief, cells were seeded in 96-well plates at a density of 2 × 10 4 cells per well. Following drug treatment, cells were washed three times with PBS, incubated with 10 μM DCFH-DA for 30 min at 37°C in the dark, and washed three times with PBS to remove the extracellular DCFH-DA. The fluorescence emission intensity of DCF (525 nm) was measured in response to 488 nm excitation. The level of intracellular ROS was expressed as the percentage of control cultures incubated in DCFH-DA and the quantification of mean optical density was analyzed by Image-pro plus 5.1 software.
2.7. Statistical Analysis
All values were expressed as the mean ± standard deviation (SD). The statistical analyses were then completed with one-way analysis of variance (ANOVA) and Student’s t-test. Differences were considered significant at p < 0.05.
3.1. A Stable Cell Model Overexpressing Human APP695 (N2a-APP695) and APPsw (N2a-APPswe) Was Established
To resemble APP expression and Aβ secretion, a N2a cell line overexpressing the human APP Swedish mutant was developed (Figure 1). Green fluorescence can be observed in transfected cells (a). The APP protein revealed a major band at 86 kDa (b), and its expression was significantly increased in N2a-APP695 (p<0.05) and N2a-APPsw cells (p<0.01) compared with N2a cells (c). Immunofluorescence intensity was performed to assess the Aβ level, and N2a-APPsw cells exhibited an increased Aβ level compared with N2a (p<0.01) and N2a-APP695 cells (p<0.05) (d & e).
3.2. EGb Optimal Concentration Screening
To evaluate the effect of EGb on the viability of N2a-APPsw cells, cells were treated with different doses of EGb (50, 100, 200, or 400 μg/ml) for 8 h (Figure 2). The data showed that cells cultured in 100 μg/ml EGb exhibited the highest cell viability (p<0.01); thus, in the following experiments for the determination of survival in response to different treatments, the optimum concentration of EGb was 100 μg/ml. Cells in the control group were treated with vehicle alone.
3.3. EGb Reduced ROS Production in N2A-APPsw Cells
The relative fluorescence intensity of ROS in N2a cells without any treatment was chosen as the stanard. ROS levels were significantly increased in N2a-APPsw cells (p<0.001). EGb was significantly reduced ROS levels. As the drug intervention time increased, ROS levels continued to decrease in cells. At 8 h, the effect of the drug was clear: the production of ROS in the cells was significantly decreased (p<0.05), and there was no significant difference compared with the control group (Figure 3).
3.4. EGb Reduced MDA Production in N2a-APPsw Cells
The concentration of MDA is an indicator of oxidative stress. As shown in Figure 4, intracellular MDA concentrations were significantly increased in N2a-APP695 and N2a-APPsw cells compared with the negative control group cells (p<0.001). However, after treatment with 100 μg/ml EGb, the activity of MDA in cell homogenates was significantly decreased compared with the activity before drug treatment (p<0.01).
3.5. EGb Increased T-SOD, CAT, and GSH-Px Levels in N2a-APPsw Cells
As shown in Figure 5, intracellular T-SOD, CAT, and GSH-Px concentrations were significantly decreased in N2a-APP695 and N2a-APPsw cells compared with the concentrations in control group cells (T-SOD, p<0.001; CAT, p<0.05; GSH-Px, p<0.05). After treatment with 100 μg/ml EGb, the activities of T-SOD, CAT, and GSH-Px in N2a-APPsw cell homogenates were significantly increased compared with the activities before drug treatment (T-SOD, p<0.001; CAT, p<0.05; GSH-Px, p<0.01).
3.6. EGb Decreased the Expression of Aβ in N2a-APPsw Cells
In addition to plaques, the excessive accumulation of Aβ can also lead to mitochondrial dysfunction, such as mitochondrial depolarization and oxidative stress. Thus, we examined the effect of EGb on the expression of Aβ in N2a, N2a-APP695, and N2a-APPsw cells. As shown by the immunofluorescence results shown in (Figure 6) (a), the expression of Aβ in N2a-APPsw cells was significantly increased (p<0.001). As expected, EGb was able to reduce intracellular Aβ compared with the control group (p <0.01) (b).
Aβ peptides are considered the primary pathological agents in AD. As a precursor protein of Aβ, APP is a protein that has been widely studied in the field of AD pathology [17, 18]. APP-transfected neuron-like cells have robust expression of APP and make for a reliable system to produce Aβ production in vitro, which can model the pathological characteristics of AD . Therefore, the N2a cell line stably overexpressing human APP695 and its Swedish mutant APPsw was used as the research model in this study. As measured by inverted fluorescence microscopy, the expression level of the APP protein and Aβ in N2a-APPsw cells indicated that the cell model was successfully constructed in vitro and could be used in subsequent experiments. The advantage of this cell line is that it stabilizes the overexpression of human APP695 and its Swedish mutants, reducing individual differences between cells and better simulating the in vivo environment.
The currently available synthetic compounds that are applied in the treatment of neurodegenerative diseases such as AD have failed to work as initially expected and often induce various side effects . Therefore, natural compounds with potentially multiple targets of neuroprotective effects derived from plants, such as curcumin, vitamin C, and Gingko biloba, have been investigated intensively in recent years .
EGb is a highly effective oxygen free radical scavenger. It can inhibit lipid peroxidation and inflammation, and its protective effect on the central nervous system is closely related to its antioxidation effect. It also is used as a vasodilator to treat ischemic conditions of the brain, renal, lung, and hear [22–25]. In addition, EGb was shown to relieve DSS-induces acute experimental colitis by promoting apoptosis [14, 25, 26]. To explore the effect of EGb on the activity of transfected APPsw cells, we treated cells with different concentrations of EGb for 8 h. We found that 100 μg/ml EGb significantly increased the activity of cells. However, the activity of cells was decreased with the increased concentration. This result indicated that EGb within a dose range is protective for cell growth but beyond that can be detrimental.
Oxidative stress is also a significant pathological feature of the neurodegenerative disease, such as Parkinson’s disease , Huntington’s disease , and Alzheimer’s disease (AD) [29, 30]. Oxidative stress is the condition that can result from an imbalance in reactive oxygen species (ROS), and that is a key mechanism of cell death. The overproduction of ROS, such as free radicals, superoxide, and hydrogen peroxide, can damage the physiological functions of cellular proteins, lipids, nucleic acids, and other macromolecules directly or indirectly . In the current study, the results showed that the ROS concentration in N2a-APPsw cells was higher than the level in N2a-APP695 and N2a normal cells. However, after treatment with 100 μg/ml of EGb, the ROS content was decreased, and it decreased to the lowest at 8 h in N2a-APP695 cells and N2a-APPsw cells. This demonstrated that increased Aβ expression in N2a-APPsw cells stimulates the increase of ROS. Aβ induces the production of oxygen free radicals, and proteins and lipids in the cell membrane system of the brain are oxidized , which increases the production of ROS. In addition, aggregation of Aβ reduces mitochondrial redox activity, resulting in the accumulation of ROS. We found that EGb reduced ROS production as well as aggregation of Aβ and had the best protective effect in N2a-APPsw cells at 8 h.
Furthermore, we also examined the concentrations of MDA. The metabolism of lipid peroxides produces MDA, indirectly reflecting the severity of free radical attack by. Consistent with previous results , we found that the concentration of MDA was significantly increased in N2a-APPsw cells. However, it was significantly decreased by EGb treatment.
T-SOD, CAT, and GSH-Px are the most important antioxidant enzymes that act against oxygen free radicals and regulate the metabolism of free radicals in the body and play a role in the free radical scavenging system, protecting the cells in the body from lipid peroxidation. The large amount of ROS reacts with biomacromolecules and unsaturated fatty acids to reduce the activity of antioxidant enzymes. Therefore, the activities of T-SOD, CAT, and GSH-Px reflect the ability of the body to scavenge oxygen free radicals. In this study, the concentrations of T-SOD, CAT and GSH-Px were remarkably decreased in the model cells, and EGb significantly increased the concentrations of T-SOD, CAT, and GSH-Px.
Therefore, we deduced that the concentrations of ROS, MDA, T-SOD, CAT, and GSH-Px were implicated in the development of AD and that EGb played its neuroprotective roles by increasing the expression of T-SOD, CAT, and GSH-Px or by decreasing both ROS and MDA to exert a direct free radical scavenging effect. Aβ deposition in the brain was related to the increased oxidative stress in AD patients and transgenic mouse models of AD [7, 34]. Aβ production has been shown to increase following events of oxidative stress and neuronal energy reduction [19, 35, 36]. Our results suggested that EGb can reduce oxidative stress and Aβ production, which may directly interact with one another in N2a-APP695 and N2a-APPsw cells.
Ginkgo biloba is currently the most widely used herb in the study of cognitive disorders and AD. However, its efficacy in preventing and treating dementia remains unclear . Some research shown the value of EGb for treating AD has become increasingly negative . However, it was verified that compounds contained in the EGb can cross the blood-brain barrier and inhibit the production of free radicals to cause pharmacological effects. Ginkgolides, biologically active terpenic lactones in Ginkgo biloba, are scavengers of reactive oxygen species and can inhibit Aβ-induced cell death . The bilobalide also has strong antioxidant activity and can promote expression of growth factors and lead neural to growth . Numerous studies in animals, healthy elderly humans, and AD patients indicated that EGb has shown protective properties against vascular and neuronal damage [41, 42] and the significant improvement in cognitive function [43, 44]. In our study, we also demonstrated that EGb plays an important role in combating oxidation and attenuating the expression of Aβ in N2a-APPsw cells. Thus, EGb might be a potential therapeutic agent for AD. In the next study, we will focus on the underlying mechanisms of EGb’s antioxidative effects in AD.
The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest
The authors declare no conflicts of interest.
Haiying Ma and Haiying Chu conceived and designed the experiments. Chenghong Zhang, Le Chen, Ying Zhang, Ying Han, and Xianyi Meng performed the experiments. Haiying Ma and Haiying Chu contributed reagents/materials. Le Chen and Haiying Ma wrote the paper. All the authors are responsible for the data reported and all of them participated in the discussion on the manuscript. Le Chen and Chenghong Zhang contributed equally to this study.
This work was supported by grants no. 31300812 from the National Natural Science Foundation of China and no. 20180550468 from Natural Science Foundation of Liaoning Province and Liaoning Provincial Program for Top Discipline of Basic Medical Sciences.
- C. Liu, G. Cui, M. Zhu, X. Kang, and H. Guo, “Neuroinflammation in Alzheimer's disease: Chemokines produced by astrocytes and chemokine receptors,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 12, pp. 8342–8355, 2014.
- D. Praticò, K. Uryu, S. Leight, J. Q. Trojanoswki, and V. M.-Y. Lee, “Increased lipid peroxidation precedes amyloid plaque formation in an animal model of alzheimer amyloidosis,” The Journal of Neuroscience, vol. 21, no. 12, pp. 4183–4187, 2001.
- E. Ferreiro, I. Baldeiras, I. L. Ferreira et al., “Mitochondrial- and endoplasmic reticulum-associated oxidative stress in alzheimer's disease: from pathogenesis to biomarkers,” International Journal of Cell Biology, vol. 2012, Article ID 735206, 12 pages, 2012.
- M. Padurariu, A. Ciobica, L. Hritcu, B. Stoica, W. Bild, and C. Stefanescu, “Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease,” Neuroscience Letters, vol. 469, no. 1, pp. 6–10, 2010.
- W. Xu, A. M. Weissmiller, J. A. White et al., “Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration,” The Journal of Clinical Investigation, vol. 126, no. 5, pp. 1815–1833, 2016.
- K. N. Manolopoulos, L.-O. Klotz, P. Korsten, S. R. Bornstein, and A. Barthel, “Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress,” Molecular Psychiatry, vol. 15, no. 11, pp. 1046–1052, 2010.
- E. Tönnies and E. Trushina, “Oxidative stress, synaptic dysfunction, and alzheimer's disease,” Journal of Alzheimer's Disease, vol. 57, no. 4, pp. 1105–1121, 2017.
- C. Cheignon, M. Tomas, D. Bonnefont-Rousselot, P. Faller, C. Hureau, and F. Collin, “Oxidative stress and the amyloid beta peptide in Alzheimer's disease,” Redox Biology, vol. 14, pp. 450–464, 2018.
- D. J. Bonda, X. Wang, G. Perry et al., “Oxidative stress in Alzheimer disease: a possibility for prevention,” Neuropharmacology, vol. 59, no. 4-5, pp. 290–294, 2010.
- J. Apelt, M. Bigl, P. Wunderlich, and R. Schliebs, “Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology,” International Journal of Developmental Neuroscience, vol. 22, no. 7, pp. 475–484, 2004.
- E. Tamagno, M. Guglielmotto, M. Aragno et al., “Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein,” Journal of Neurochemistry, vol. 104, no. 3, pp. 683–695, 2008.
- I. Baldeiras, I. Santana, M. T. Proença et al., “Oxidative damage and progression to alzheimer's disease in patients with mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 21, no. 4, pp. 1165–1177, 2010.
- M. A. Lovell and W. R. Markesbery, “Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease,” Nucleic Acids Research, vol. 35, no. 22, pp. 7497–7504, 2007.
- Y. Sun, L.-J. Lin, Y. Lin, L.-X. Sang, M. Jiang, and C.-Q. Zheng, “Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 10, pp. 17235–17247, 2015.
- L. Han and M. Li, “Protection of vascular endothelial cells injured by angiotensin II and hypoxia in vitro by Ginkgo biloba (Ginaton),” Vascular and Endovascular Surgery, vol. 47, no. 7, pp. 546–550, 2013.
- D. T. Peng et al., “Study on the mechanism of Alzheimer disease-related gene presenilin-1,” Chinese Journal of Internal Medicine, vol. 42, no. 8, p. 537, 2003.
- M. A. Lovell, W. D. Ehmann, S. M. Butler, and W. R. Markesbery, “Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease,” Neurology, vol. 45, no. 8, pp. 1594–1601, 1995.
- K. J. Barnham, C. L. Masters, and A. I. Bush, Neurodegenerative diseases and oxidative stress [Masters, thesis], 2004.
- J. J. Kong et al., “Nicorandil inhibits oxidative stress and amyloid-β precursor protein processing in SH-SY5Y cells overexpressing APPsw,” International Journal of Clinical & Experimental Medicine, vol. 8, no. 2, p. 1966, 2015.
- L. Shi, L. Zhang, H. Li et al., “Protective effects of curcumin on acrolein-induced neurotoxicity in HT22 mouse hippocampal cells,” Pharmacological Reports, vol. 70, no. 5, pp. 1040–1046, 2018.
- A. Wąsik and L. Antkiewicz-Michaluk, “The mechanism of neuroprotective action of natural compounds,” Pharmacological Reports, vol. 69, no. 5, pp. 851–860, 2017.
- Z. Y. Meng, “Efficacy of osthole in management of hypoperfused retina,” Journal of Ophthalmology, vol. 2018, 2018.
- Q. M. Xiao, “Effects of extract of Ginkgo biloba on magnetic resonance imaging and electroencephalography in patients with delayed encephalopathy after acute carbon monoxide poisoning,” Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, vol. 35, no. 2, pp. 145–147, 2017.
- R. Bridi, F. P. Crossetti, V. M. Steffen, and A. T. Henriques, “The antioxidant activity of standardized extract of Ginkgo biloba (EGb 761) in rats,” Phytotherapy Research, vol. 15, no. 5, pp. 449–451, 2001.
- V. S. Kotakadi, Y. Jin, A. B. Hofseth et al., “Ginkgo biloba extract EGb 761 has anti-inflammatory properties and ameliorates colitis in mice by driving effector T cell apoptosis,” Carcinogenesis, vol. 29, no. 9, pp. 1799–1806, 2008.
- R. Quinlivan and R. Quinlivan, “European handbook of neurological management,” in Neuromuscular Disorders, R. Hughes, M. Brainin, and N. E. Gilhus, Eds., vol. 17, p. 351, 2007, £120, ISBN: 1405130504.
- P. Pan, L. Qiao, and X. Wen, “Safranal prevents rotenone-induced oxidative stress and apoptosis in an in vitro model of Parkinson's disease through regulating Keap1/Nrf2 signaling pathway,” Cellular and Molecular Biology, vol. 62, no. 14, p. 11, 2017.
- E. Machiela, D. J. Dues, M. M. Senchuk, and J. M. Van Raamsdonk, “Oxidative stress is increased in C. elegans models of Huntington’s disease but does not contribute to polyglutamine toxicity phenotypes,” Neurobiology of Disease, vol. 96, pp. 1–11, 2016.
- M. F. Beal, “Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment,” Neurobiology of Aging, vol. 26, no. 5, pp. 585-586, 2005.
- A. García-Blanco, M. Baquero, M. Vento, E. Gil, L. Bataller, and C. Cháfer-Pericás, “Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease,” Journal of the Neurological Sciences, vol. 373, pp. 295–302, 2017.
- Y. Hui et al., “Resveratrol Attenuates the Cytotoxicity Induced by Amyloid-beta1-42 in PC12 Cells by Upregulating Heme Oxygenase-1 via the PI3K/Akt/Nrf2 Pathway,” Neurochemical Research, vol. 43, no. 2, pp. 297–305, 2018.
- D. A. Butterfield, A. Castegna, C. M. Lauderback, and J. Drake, “Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death,” Neurobiology of Aging, vol. 23, no. 5, pp. 655–664, 2002.
- M. D. Pandareesh, V. Chauhan, and A. Chauhan, “Walnut supplementation in the diet reduces oxidative damage and improves antioxidant status in transgenic mouse model of alzheimer’s disease,” Journal of Alzheimer's Disease, vol. 64, no. 4, pp. 1295–1305, 2018.
- A. Thapa, “Dietary modulation of oxidative stress in alzheimer's disease,” International Journal of Molecular Science, vol. 18, no. 7, p. E1583, 2017.
- D. A. Butterfield, T. Reed, S. F. Newman, and R. Sultana, “Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment,” Free Radical Biology & Medicine, vol. 43, no. 5, pp. 658–677, 2007.
- D. G. Jo et al., “Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer's disease,” Alzheimers Dementia the Journal of the Alzheimers Association, vol. 8, no. 4, pp. 917–925, 2010.
- M. Canevelli, N. Adali, E. Kelaiditi, C. Cantet, P. Ousset, and M. Cesari, “Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study,” Phytomedicine, vol. 21, no. 6, pp. 888–892, 2014.
- J. Birks et al., “Ginkgo biloba for cognitive impairment and dementia,” Alzheimer & Dementia, vol. 2, no. 3, p. S367, 2006.
- C. Bate, M. Tayebi, and A. Williams, “Ginkgolides protect against amyloid-β1-42 -mediated synapse damage in vitro,” Molecular Neurodegeneration, vol. 3, no. 1, p. 1, 2008.
- F. Tchantchou, P. N. Lacor, Z. Cao et al., “Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons,” Journal of Alzheimer's Disease, vol. 18, no. 4, pp. 787–798, 2009.
- T. Yoshitake, S. Yoshitake, and J. Kehr, “The Ginkgo biloba extract EGb 761®; and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex,” British Journal of Pharmacology, vol. 159, no. 3, pp. 659–668, 2010.
- R. Ihl, “Effects of Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials,” International Journal of Psychiatry in Clinical Practice, vol. 17, no. 1, pp. 8–14, 2013.
- M. Hashiguchi et al., “Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia,” Journal of Pharmaceutical Health Care and Sciences, vol. 1, no. 1, p. 14, 2015.
- G. Yang, Y. Wang, J. Sun, K. Zhang, and J. Liu, “Ginkgo biloba for mild cognitive impairment and alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials,” Current Topics in Medicinal Chemistry, vol. 16, no. 5, pp. 520–528, 2016.
Copyright © 2019 Le Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.